Getting a stage 3 melanoma diagnosis brings a lot of information at once. This article explains what your pathology report means and reviews support methods that research has looked at alongside standard treatment.
Your pathology report is a written record of what the laboratory found in your tissue sample. Every number and term affects how your doctor stages the cancer, what treatment you’ll get, and what to expect.
| Substage | Primary Tumor Features | Regional Spread | Approximate 5-Year Survival |
|---|---|---|---|
| IIIA | T1 or T2 thickness, not ulcerated | Cancer cells in 1 to 3 lymph nodes, visible only under a microscope | Approximately 93% |
| IIIB | T1 or T2 with ulceration, or T3 without ulceration; or in-transit or satellite lesions present | Cancer cells visible only under a microscope, or no cancer in lymph nodes | Intermediate – between IIIA and IIIC |
| IIIC | Thicker or ulcerated primary tumor | Multiple positive nodes or cancer in lymph nodes detected on exam or imaging | Intermediate – below IIIB |
| IIID | Any thickness with ulceration | 4 or more positive nodes, or fused nodes | Approximately 32% |
Survival figures for IIIA (approximately 93%) and IIID (approximately 32%) are from a 2021 analysis in PMC via the National Institutes of Health. Intermediate rates for IIIB and IIIC vary by study and are presented qualitatively here. Staging criteria follow the AJCC 8th edition as described by the American Cancer Society and Cancer Research UK.
What Stage 3 Melanoma Means
Stage 3 means cancer has spread beyond your skin but hasn’t reached distant organs like the lungs or liver. The cancer is in nearby areas. Cancer cells have moved into nearby lymph nodes, formed small clusters between the primary tumor and the lymph nodes (satellite lesions), or traveled through skin and fat between the primary site and the regional nodes (in-transit metastases). According to the American Cancer Society, stage 3 is divided into substages IIIA through IIID based on the extent of regional spread and whether the original tumor showed ulceration.
Key Terms in Your Pathology Report
Several measurements appear in every melanoma pathology report. Each one plays a direct role in staging and treatment selection.
Breslow Thickness
Breslow thickness is the depth of the tumor measured in millimeters from the skin surface to the deepest cancer cell. It is the single strongest predictor of how likely the cancer is to spread. A 2021 research review in PMC via the National Institutes of Health lists Breslow thickness as one of the most important factors in stage III melanoma. Tumors 1 mm or thinner are considered thin; 4 mm or greater are considered thick.
Ulceration
Ulceration means the surface skin over the tumor has broken down. Its presence places the tumor in a higher category within the AJCC staging system. Research published in PMC (NCBI) confirmed that ulceration makes survival rates worse across stages I through III melanoma.
Mitotic Rate
The mitotic rate counts how many tumor cells are actively dividing per square millimeter of tissue. A higher number means faster tumor growth. The same NIH-indexed review found that mitotic rate helps predict whether cancer will spread and how long you’ll survive, alongside Breslow thickness and ulceration.
BRAF, NRAS, and KIT Mutation Status
Molecular testing of the tumor checks for gene mutations that guide treatment selection. The BRAF V600E or V600K mutation is present in roughly 50% of melanomas. Patients with a BRAF V600 mutation may be candidates for targeted therapy combining a BRAF inhibitor with a MEK inhibitor, along with immunotherapy or as an alternative to it. NRAS and KIT mutations are less common but also affect the treatment you get. Your oncologist will review these results with you.
Lymph Node Findings
Most stage 3 diagnoses involve a sentinel lymph node biopsy – a procedure that removes and tests the first nodes that cancer drains to. The report will state how many nodes were sampled, how many tested positive, and the size of any cancer deposits found. According to Cancer Research UK, stage 3 classification is based on the number of involved nodes, the size of deposits within those nodes, and whether the primary tumor was ulcerated.
Your Substage: IIIA Through IIID
Substage matters because outcomes vary widely across stage 3. The 2021 PMC analysis cited above reported 5-year survival rates from approximately 93% at IIIA to approximately 32% at IIID. These are averages for all people. Your outcome depends on tumor biology, how well you respond to treatment, and your overall health.
- Stage IIIA: The original tumor was thin (T1 or T2) and not ulcerated. Cancer appeared in only 1 to 3 lymph nodes, visible only under a microscope. This substage carries the most favorable outlook within stage 3.
- Stage IIIB: The tumor was T1 or T2 with ulceration, or T3 without ulceration – or in-transit and satellite lesions exist without lymph node involvement. Prognosis is intermediate.
- Stage IIIC: Involves thicker or ulcerated primary tumors with lymph node involvement, multiple positive nodes, or cancer in lymph nodes detected on physical exam or imaging. Prognosis is below IIIB.
- Stage IIID: Any tumor thickness with ulceration and four or more involved nodes, or fused nodes. This substage carries the highest recurrence risk within stage 3.
Standard Treatment Approaches
For most patients with stage 3 melanoma, surgery to remove the primary tumor and involved lymph nodes is the first step. Adjuvant therapy after surgery aims to reduce the risk of the cancer returning.
Checkpoint Inhibitor Immunotherapy
Drugs that block the PD-1 checkpoint – including nivolumab and pembrolizumab – are approved for adjuvant use after complete removal of stage 3 melanoma, regardless of BRAF mutation status. A clinical-practice review in PMC (NCBI) found that adjuvant anti-PD-1 immunotherapy helped people stay cancer-free longer in a real-world stage III population. Side effects from these drugs can be significant and immune-related. Caregivers supporting someone through this phase will find the article Caregiver Guide to Melanoma Immunotherapy Side Effects useful for understanding what to monitor and when to call the oncology team.
Targeted Therapy for BRAF-Mutant Melanoma
Patients with BRAF V600E or V600K mutations may be offered a BRAF inhibitor combined with a MEK inhibitor along with immunotherapy or as an alternative to it. The COMBI-AD trial, cited in the PMC review above, reported 52% recurrence-free survival at 5 years with this combination versus 36% with placebo among patients with removed stage III BRAF-mutant melanoma. Your oncologist will determine whether immunotherapy, targeted therapy, or both is most appropriate for your substage and health profile.
Integrative Support: What the Evidence Suggests
Integrative approaches are studied as additions to conventional care, not as replacements. They may support immune function, help manage side effects, and help you feel better. Always tell your oncologist about any supplement or dietary change before starting, as some compounds can interact with immunotherapy or targeted therapy.
Nutrition and Body Weight
A 2021 systematic review in PMC (NCBI) examined nutritional interventions in melanoma patients. The most consistent evidence supported a Mediterranean-style eating pattern, keeping a healthy weight, and reduction of alcohol intake. The authors noted that randomized controlled trials in this area remain limited, and no specific dietary prescription can be made with confidence at this time.
Vitamin D
Melanoma cells have vitamin D receptors, and lower blood vitamin D levels have been associated with more aggressive disease in observational studies. A meta-analysis in PMC (NCBI) examined associations between dietary vitamin D intake, serum levels, and how aggressive the cancer appears. Because sun avoidance is strongly recommended after a melanoma diagnosis, vitamin D made by your skin may fall. Your oncologist can order a blood test to check your vitamin D level and advise on whether taking vitamin D supplements is appropriate and at what dose. For more detail on dose ranges and immune-support evidence in the melanoma context, see Melanoma Survivorship and Vitamin D.
Green Tea Extract (EGCG)
A 2023 nutrient-based review in PMC (NCBI) identified a compound in green tea called EGCG that affects how melanoma cells grow and die in the lab and in animal studies. Human clinical data in melanoma patients remain preliminary, and no standard therapeutic dose has been set by current clinical guidelines. If you want to try a green tea supplement, look for one with a standardized extract. Talk to your oncologist about the right dose for you. Check with your oncologist about this choice, particularly during immunotherapy, as EGCG can affect how your body uses cancer drugs.
Melatonin
Melatonin affects your immune system and helps with cell damage, which has generated interest alongside cancer treatment. A 2025 review in PMC (NCBI) summarized evidence that melatonin may help support cancer treatment through effects on cell damage, killing cancer cells, and boosting your immune system, while cautioning that well-designed human clinical trials remain limited. Doses studied in cancer research range from 10 mg to 20 mg taken at night. Talk to your oncologist before starting melatonin, as how it works with checkpoint inhibitor immunotherapy isn’t fully understood.
Questions to Ask Your Care Team
Before leaving your first treatment planning appointment, it helps to ask:
- What is my exact substage and what does it mean for my treatment options?
- Did my tumor test positive for BRAF V600, and how does that affect the choices available to me?
- Will you recommend adjuvant immunotherapy, targeted therapy, or a combination?
- What side effects should I watch for and who do I contact if they appear?
- Should I have my vitamin D level checked, and what range are you aiming for?
- Are there supplements or foods I should avoid during my treatment?
- Am I a candidate for a current clinical trial at my substage?
If you are taking prescription medication, are pregnant, or are breastfeeding, speak with your clinician before adding any supplement or dietary change. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
